Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Minato-ku, TokyoFounded 2000704 employeesWebsite
Operates 'm3.com,' Japan's largest portal for healthcare professionals. A global leader in medical DX, specializing in pharmaceutical marketing support and clinical trial services.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Medical Platform Services | 35% | ¥107.8B | ¥35.9B | 33.3% |
| International Financial Services | 28% | ¥86.9B | ¥14.9B | 17.1% |
| Patient-Centric Solutions | 19% | ¥56.9B | ¥2.7B | 4.7% |
| Medical Site Solutions | 18% | ¥54.4B | ¥5.8B | 10.6% |
Close (Oct 30, 2026)
¥1,840.5-13.3% (1Y)
M3 -13.3% over 1Y. Rivals (reference): JMDC -21.2%, Medley +15.4%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥351.4B | ¥73.5B | ¥49.1B | ¥637.4B | +23.3% |
| 2025FY | ¥284.9B | ¥63.0B | ¥40.5B | ¥581.7B | +19.3% |
| 2024FY | ¥238.9B | ¥64.4B | ¥45.3B | ¥490.8B | +3.5% |
| 2023FY | ¥230.8B | ¥72.0B | ¥49.0B | ¥400.6B | +10.9% |
| 2022FY | ¥208.2B | ¥95.1B | ¥63.8B | ¥346.0B | +23.0% |
| 2021FY | ¥169.2B | ¥58.0B | ¥37.8B | ¥273.1B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jun 2025)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
